Citi downgraded Establishment Labs to Neutral from Buy with an unchanged price target of $60. The analyst cites valuation for the downgrade. The stock is up 103% year-to-date and expectations are now appropriately set for U.S. approval in 2024, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs reports Q1 EPS (58c), consensus (67c)
- Establishment Labs price target raised to $62 from $53 at BTIG
- Establishment Labs price target raised to $60 from $49 at Citi
- Establishment Labs says FDA schedules preapproval inspection for Motiva facility
- Establishment Labs participates in a conference call with JPMorgan